A 32-year-old woman with unexplained infertility is being considered for gonadotropin therapy vs. GnRH agonist co-treatment. Which clinical feature best distinguishes the risk profile and outcome of gonadotropin monotherapy from GnRH agonist + gonadotropin combination in terms of ovarian hyperstimulation and follicle development?

Explanation

## Gonadotropin Monotherapy vs. GnRH Agonist Co-treatment ### Gonadotropin Monotherapy (Conventional IVF) **Key Point:** Exogenous gonadotropins (FSH ± hCG) without pituitary suppression. 1. Endogenous GnRH and gonadotropins remain active 2. Endogenous LH surge can occur during follicle development 3. **Premature ovulation risk** — uncontrolled LH surge 4. **Higher OHSS risk** — endogenous LH amplifies steroid production 5. Requires careful monitoring and hCG trigger timing 6. Simpler protocol; lower drug cost ### GnRH Agonist + Gonadotropin (Long Protocol) **Key Point:** GnRH agonist suppresses pituitary → exogenous gonadotropins control follicle development. 1. Initial GnRH agonist causes flare (↑ FSH/LH), then downregulation 2. Pituitary becomes insensitive to endogenous GnRH 3. **Prevents premature LH surge** — no endogenous ovulation 4. **Lower OHSS risk** — LH suppression reduces steroid production 5. Better cycle control; more predictable follicle development 6. Requires higher gonadotropin doses (due to pituitary suppression) 7. Higher drug cost; longer protocol duration ### Discriminating Feature: OHSS Risk & LH Surge Prevention | Feature | Gonadotropin Monotherapy | GnRH Agonist + Gonadotropin | |---------|--------------------------|-----------------------------| | **Endogenous LH** | Active; can surge | Suppressed; no surge | | **Premature ovulation** | Risk present | Prevented | | **OHSS incidence** | Higher (5–10%) | Lower (2–5%) | | **Mechanism of OHSS ↓** | N/A | LH suppression → ↓ steroid synthesis | | **Follicle synchrony** | Less uniform | More uniform | | **Gonadotropin requirement** | Lower | Higher | | **Cycle cancellation** | Higher (premature surge) | Lower | **High-Yield:** The **prevention of endogenous LH surge** is the key clinical advantage of GnRH agonist co-treatment. This suppression directly reduces OHSS risk and premature ovulation. **Mnemonic:** **PALS** — Pituitary suppression Avoids LH Surge (GnRH agonist benefit). **Clinical Pearl:** In high-responder patients (PCOS, young age, high AMH), GnRH agonist co-treatment is preferred to reduce OHSS risk. Gonadotropin monotherapy is reserved for poor responders or when cost/simplicity is prioritized. **Warning:** Gonadotropin monotherapy is NOT the same as "natural cycle IVF" — it uses exogenous FSH but lacks pituitary suppression. Do not confuse with truly natural (unstimulated) cycles. [cite:ASRM Guideline on Ovarian Hyperstimulation Syndrome 2016; Harrison 21e Ch 405]